Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.37 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770558 | 0.87 | AGPAT2 (0.40) | ABL1AGPAT2CTSAEPHA4MAPK14 | |
| SCHEMBL23770808 | 0.80 | HTR3E (0.38) | ABL1CCNT1MAPK14 | |
| SCHEMBL23770741 | 0.80 | ABL1 (0.35) | ABL1AGPAT2CCNT1 | |
| SCHEMBL23770715 | 0.80 | AGPAT2 (0.34) | ABL1AGPAT2CCNT1CTSAMAPK14 | |
| SCHEMBL23770831 | 0.77 | ABL1 (0.33) | ABL1AGPAT2CTSA | |
| SCHEMBL23770554 | 0.75 | DPP4 (0.33) | CCNT1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL23770637 | 0.74 | PDE4B (0.38) | AGPAT2CCNT1CTSA | |
| SCHEMBL23770776 | 0.74 | ABL1 (0.38) | ABL1AGPAT2CCNT1EPHA4MAPK14 | |
| SCHEMBL23770590 | 0.73 | ADORA2A (0.35) | EPHA4 | |
| SCHEMBL23770546 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |